logo
  

VF Corp. Boosts FY22 Outlook; Declares Dividend - Quick Facts

While reporting financial results for the first quarter of fiscal 2022 on Friday, VF Corp. (VFC) raised its adjusted earnings and revenue guidance for the full-year 2022.

For fiscal 2022, the company now projects adjusted earnings to be approximately $3.20, including an approximate $0.25 contribution from the Supreme brand.

The company also now expects full-year revenues to be approximately $12.0 billion, reflecting growth of approximately 30 percent, including an approximate $600 million contribution from the Supreme brand.

Previously, the company expected adjusted earnings to be approximately $3.05 on revenues of approximately $11.8 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.08 per share on revenues of $11.86 billion for the year. Analysts' estimates typically exclude special items.

"Though the first quarter is a relatively small portion of our total year, this strong start reinforces my confidence in our ability to accelerate growth through fiscal 2022 and beyond," said Steve Rendle, Chairman, President and CEO.

Further, VF's Board of Directors declared a quarterly dividend of $0.49 per share, payable on September 20, 2021, to shareholders of record on September 10, 2021. Subject to approval by its Board of Directors, VF intends to continue to pay its regularly scheduled dividend.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT